News

CVS Drops Lilly’s Zepbound as Preferred Drug in Win for Novo
CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...
NBC Los Angeles4h
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...
Why Novo Nordisk Stock Popped Today
Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
STAT7d
Novo Nordisk strikes telehealth deals for obesity drug, following Eli Lilly
Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...
Novo Nordisk cuts guidance as weight-loss drug market competition grows
Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth ...
Novo Nordisk teams with telehealth firms Hims, Ro to sell Wegovy at lower price
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Novo Nordisk on the back foot ahead of earnings
Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...